WO2022270956A1 - 세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 제제 조성물 - Google Patents
세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 제제 조성물 Download PDFInfo
- Publication number
- WO2022270956A1 WO2022270956A1 PCT/KR2022/008984 KR2022008984W WO2022270956A1 WO 2022270956 A1 WO2022270956 A1 WO 2022270956A1 KR 2022008984 W KR2022008984 W KR 2022008984W WO 2022270956 A1 WO2022270956 A1 WO 2022270956A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sustained
- release
- semaglutide
- viscosity
- formulation composition
- Prior art date
Links
- 238000013268 sustained release Methods 0.000 title claims abstract description 103
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 103
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 title claims abstract description 68
- 108010060325 semaglutide Proteins 0.000 title claims abstract description 68
- 229950011186 semaglutide Drugs 0.000 title claims abstract description 68
- 239000013022 formulation composition Substances 0.000 title claims abstract description 37
- 150000003839 salts Chemical class 0.000 title claims abstract description 31
- 239000004005 microsphere Substances 0.000 claims abstract description 83
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 67
- 239000000203 mixture Substances 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 28
- 241000700159 Rattus Species 0.000 claims description 26
- 239000002245 particle Substances 0.000 claims description 14
- 239000011259 mixed solution Substances 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 208000014644 Brain disease Diseases 0.000 claims description 10
- 230000003412 degenerative effect Effects 0.000 claims description 10
- 239000007921 spray Substances 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 8
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 7
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 7
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- 229960000583 acetic acid Drugs 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 239000012362 glacial acetic acid Substances 0.000 claims description 6
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 4
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 4
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 39
- 239000003814 drug Substances 0.000 abstract description 39
- 230000007774 longterm Effects 0.000 abstract description 7
- 230000000052 comparative effect Effects 0.000 description 57
- 238000009472 formulation Methods 0.000 description 33
- 239000008280 blood Substances 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 19
- 229920000642 polymer Polymers 0.000 description 19
- 229920002988 biodegradable polymer Polymers 0.000 description 12
- 239000004621 biodegradable polymer Substances 0.000 description 12
- 238000002156 mixing Methods 0.000 description 10
- 238000011068 loading method Methods 0.000 description 9
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 8
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 8
- 239000003405 delayed action preparation Substances 0.000 description 8
- -1 genticinate Chemical compound 0.000 description 8
- 108010019598 Liraglutide Proteins 0.000 description 7
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 7
- 230000001186 cumulative effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229960002701 liraglutide Drugs 0.000 description 7
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 229960005337 lysine hydrochloride Drugs 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 description 5
- 238000010254 subcutaneous injection Methods 0.000 description 5
- 239000007929 subcutaneous injection Substances 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229960003646 lysine Drugs 0.000 description 4
- 235000018977 lysine Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- 238000007410 oral glucose tolerance test Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 239000002253 acid Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 239000003509 long acting drug Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- PJRSUKFWFKUDTH-JWDJOUOUSA-N (2s)-6-amino-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]propanoyl]amino]acetyl]amino]propanoyl Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(N)=O PJRSUKFWFKUDTH-JWDJOUOUSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000006419 Glucagon-Like Peptide Receptors Human genes 0.000 description 1
- 108010083749 Glucagon-Like Peptide Receptors Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 229940084891 byetta Drugs 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 108010021753 peptide-Gly-Leu-amide Proteins 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the present invention relates to a sustained release formulation composition.
- GLP-1 RAs Glucagon-like peptide receptor agonists
- sustained-release formulations using biodegradable polymers are being developed to realize a long-term sustained release effect, but in the case of these formulations, biodegradable polymers with slow drug release to prevent drug release duration and initial excessive release.
- biodegradable polymers with slow drug release to prevent drug release duration and initial excessive release.
- the drug does not come out for a considerable period of time (2-3 weeks at the shortest, more than 1 month at the longest), or the cumulative release rate of the drug is lower than 30%.
- An object of the present invention is to provide a sustained-release formulation containing sustained-release microspheres that do not cause an initial burst of a drug, enable sustained release over a long period of time, have no lag phase, and have excellent bioavailability.
- the object of the present invention is to provide a method for producing a sustained-release formulation composition comprising sustained-release microspheres that have no initial burst of drug, allow for long-term sustained release, have no lag phase, and have excellent bioavailability.
- sustained-release microspheres containing semaglutide or a pharmaceutically acceptable salt thereof and poly(lactide-co-glycolide);
- the semaglutide or a pharmaceutically acceptable salt thereof is included in an amount of 3% by weight or more and less than 9% by weight of the sustained-release microspheres,
- the poly(lactide-co-glycolide) is a mixture of low-viscosity PLGA having an intrinsic viscosity of 0.14 to 0.24 dL/g and high-viscosity PLGA having an intrinsic viscosity of 0.32 to 0.44 dL/g.
- sustained-release formulation composition according to 1 above wherein the weight ratio of the low-viscosity PLGA and the high-viscosity PLGA in the mixture is 1: 0.2 to 5.
- sustained-release microspheres are prepared by dissolving the semaglutide or a pharmaceutically acceptable salt thereof and the poly(lactide-co-glycolide) in glacial acetic acid and spraying using an ultrasonic spray nozzle. After that, the sustained-release formulation composition prepared by volatilizing the solvent using dry air.
- the frequency of the ultrasonic spray nozzle is 60kHz, the sustained-release formulation composition.
- sustained-release formulation composition according to 1 above wherein less than 5% of the semaglutide is released within 24 hours after administration to SD rats, and 30% or more within 2 weeks or 60% or more within 4 weeks.
- sustained-release preparation composition according to 1 above which is administered to the subject at intervals of 1 to 3 months.
- sustained-release formulation composition according to 1 above wherein the poly(lactide-co-glycolide) is 91 to 97% by weight of the sustained-release microspheres.
- sustained-release formulation composition according to 1 above wherein the sustained-release microspheres have an average particle size of 15 to 25 ⁇ m.
- sustained-release formulation composition according to 1 above for the treatment of diabetes, obesity, non-alcoholic steatohepatitis or degenerative brain disease.
- the sustained-release preparation composition according to 10 above, wherein the degenerative brain disease is any one selected from the group consisting of Parkinson's disease, Alzheimer's disease, Huntington's disease, Lou Gehrig's disease, Creutzfeldt-Jakob disease, stroke, and multiple sclerosis.
- the poly(lactide-co-glycolide) is a mixture of low-viscosity PLGA having an intrinsic viscosity of 0.14 to 0.24 dL/g and high-viscosity PLGA having an intrinsic viscosity of 0.32 to 0.44 dL/g. .
- a method for treating diabetes, obesity, non-alcoholic steatohepatitis or degenerative brain disease comprising administering the sustained-release formulation composition of any one of the above 1 to 10 to a subject.
- the sustained-release formulation composition of the present invention does not have an excessive initial release of the drug and can release the drug continuously for a long period of time. In addition, there is no release delay phenomenon and the bioavailability is excellent.
- the sustained-release formulation composition of the present invention may be administered to a subject at intervals of 1 month or more.
- FIG. 1 is a schematic diagram briefly showing the release of semaglutide after subcutaneous injection of the sustained-release microspheres of the present invention.
- Figure 2 shows the in vitro initial release evaluation results (after 6 hours) of sustained-release microspheres of Examples 3 and 6 and Comparative Examples 1 to 4 formulations.
- Figure 3 shows the linear time-dependent glucose lowering effect after subcutaneous injection of semaglutide and sustained-release microspheres (PT403) of the formulation of Example 3 in SD rats. Blood glucose levels were measured using Accu-Chek 28 days after injection.
- Figure 4 shows the change in body weight after subcutaneous injection of semaglutide and sustained-release microspheres (PT403) of the formulation of Example 3 to SD rats.
- Figure 5 shows the blood of the formulations of Examples 3, 4, and 6 having semaglutide contents (Loading Capacity, LC) of 3, 4, and 6% by weight, respectively, at the same dose of 4mpk administered to male 8-week-old SD rats over time. Indicates drug concentration.
- LC Semaglutide contents
- Figure 6 shows the formulations of Examples 3, 4, and 6, each having a loading capacity (LC) of 3, 4, and 6% by weight, respectively, at the dose of 4mpk to male 8-week-old SD rats, respectively. It represents the cumulative release rate of glutide.
- LC loading capacity
- Example 7 shows the blood drug concentration over time after administration of the formulation of Example 3 to a male beagle at 4 mpk.
- Figure 8 shows the cumulative release rate of semaglutide over time after administration of the formulation of Example 3 to male beagles at 4 mpk.
- Figure 9 shows the blood drug concentration over time after administration of microspheres of the formulations of Comparative Examples 13 and 14 containing liraglutide as an active ingredient to male 8-week-old S.D. rats at 4 mpk.
- the present invention includes semaglutide or a pharmaceutically acceptable salt thereof, which has no initial burst, long-term sustained release of the drug, no lag phase, and excellent bioavailability. It relates to sustained-release microspheres and compositions containing them.
- the present invention provides a sustained-release formulation composition
- a sustained-release formulation composition comprising sustained-release microspheres containing semaglutide or a pharmaceutically acceptable salt thereof and poly(lactide-co-glycolide).
- Semaglutide is a GLP-1 receptor agonist that can be prepared as described in WO2006/097537, Example 4, N 6,26 - ⁇ 18-[N-(17-carboxyheptadecanoyl)-L- ⁇ -Glutamyl]-10-oxo-3,6,12,15-tetraoxa-9,18-diazaoctadecanoyl ⁇ -[8-(2-amino-2-propanoic acid), 34-L-arginine ] Also known as human glucan-like peptide 1 (7-37).
- the "pharmaceutically acceptable salt” of the present invention is a concentration that has an effective effect that is relatively non-toxic and harmless to patients, and refers to any salt that does not reduce the beneficial effect of semaglutide due to the side effects caused by the salt. It may be a salt or base addition salt.
- acid addition salts include, for example, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate of semaglutide.
- salicylate citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, genticinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, Glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate , fumarate, hydrochloride, 2-hydroxyethanesulfonate (isethionate), nicotinate, 2-naphthalenesulfonate, oxalate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate , propionate, succinate, tartrate, thiocyanate,
- the base addition salt may be, for example, an alkali metal salt, an alkaline earth metal salt, or a quaternary ammonium salt of semaglutide.
- Semaglutide or a pharmaceutically acceptable salt thereof contained in the sustained-release microspheres of the present invention is less than 9% by weight based on the total weight of the sustained-release microspheres, preferably 3% by weight or more and less than 9% by weight or 3% by weight. % or more and 8.8 wt% or less, 3 wt% or more and 8.5 wt% or less, 3 wt% or more and 8.2 wt% or less, 3 wt% or more and 8 wt% or less, or 3 wt% or more and 6 wt% or less.
- semaglutide or its pharmaceutically acceptable salt When the content of semaglutide or its pharmaceutically acceptable salt is 3% by weight or more and 10% by weight or less, the bioavailability is excellent, but when the content of semaglutide or its pharmaceutically acceptable salt is 9% by weight or more, the initial release rate is rapid.
- semaglutide or a pharmaceutically acceptable salt thereof is preferably included in an amount of 3% by weight or more and less than 9% by weight based on the total weight of the sustained-release microspheres.
- Polylactide-co-glycolide (PLGA) included in the sustained-release microspheres of the present invention has a low viscosity PLGA of 0.14 to 0.24 dL/g and an intrinsic viscosity of 0.32 to 0.44 dL/g. It may be a mixture of phosphorus high viscosity PLGA.
- the weight ratio of low-viscosity PLGA having an intrinsic viscosity of 0.14 to 0.24 dL/g and high-viscosity PLGA having an intrinsic viscosity of 0.32 to 0.44 dL/g was 1: 0.2 to 5, 1: 0.2 to 3, 1: 0.3 to 5, 1: 0.3 to 3, 1: 0.5 to 5, 1: 0.5 to 3, 1: 0.5 to 2, 1: 1 to 5, 1: 1 to 3, 1: 1 to 2.5, 1: 1.5 to 2.5 or 1: 1.8 to 2.2, preferably 1: 1.8 to 2.2.
- the poly(lactide-co-glycolide) included in the sustained-release microspheres consists of only low-viscosity PLGA, the initial release amount of semaglutide becomes too large. , there is a problem that the release delay (Lag phase) may occur and the overall release amount is reduced to lower the bioavailability.
- the sustained-release microspheres of the present invention include a poly(lactide-co-glycolide) mixture in which low-viscosity PLGA having an intrinsic viscosity of 0.14 to 0.24 dL/g and high-viscosity PLGA having an intrinsic viscosity of 0.32 to 0.44 dL/g are mixed.
- low-viscosity PLGA and high-viscosity PLGA are mixed at a weight ratio of 1:0.2 to 5, more preferably low-viscosity PLGA and high-viscosity PLGA are mixed at a weight ratio of 1:1.8 to 2.2, so that the initial stage of semaglutide Excessive release does not occur, there is no release delay (Lag phase), and the bioavailability is excellent.
- the intrinsic viscosity (IV) of poly(lactide-co-glycolide) (Polylactide-co-glycolide, PLGA) of the present invention is 25 Viscosity measured using an Uberroude viscometer at °C.
- Low-viscosity PLGA with an intrinsic viscosity of 0.14 to 0.24 dL/g has a molar ratio of lactide to glycolide of 80 to 45:50, 80 to 70:50, 75 to 50:50, 70 to 45:50, 65 to It may be 50:50 or 55 to 45:50, preferably 55 to 45:50.
- examples of low-viscosity PLGA having an intrinsic viscosity of 0.14 to 0.24 dL/g include RG502, RG502H, RG752H, and RG752S from Evonik.
- High-viscosity PLGA with an intrinsic viscosity of 0.32 to 0.44 dL/g has a molar ratio of lactide to glycolide of 80 to 45:50, 75 to 50:50, 70 to 45:50, 65 to 50:50 or 55 to 45 : 50, preferably 55 to 45:50.
- examples of high-viscosity PLGA having an intrinsic viscosity of 0.32 to 0.44 dL/g include RG503, RG503H, RG653H, RG752H, and RG753S from Evonik.
- the mixture may contain 80% by weight or more or 90% by weight or more based on the total weight of the microspheres, more specifically 90 to 99% by weight, 90 to 97% by weight, 90 to 96% by weight, 91 to 99% by weight, 91 to 97 wt%, 91 to 96 wt%, 92 to 99 wt%, 92 to 97 wt%, 92 to 96 wt%, 93 to 99 wt%, 93 to 97 wt%, 93 to 96 wt%, 94 to 94 wt% 99% by weight, 94 to 97% by weight or 94 to 96% by weight may be included.
- sustained-release microspheres of the present invention contain, for example, 3% by weight or more and less than 9% by weight of semaglutide or a pharmaceutically acceptable salt thereof, 90 to 97% by weight or 91 to 97% by weight of poly(lactide-co- glycolide) may be included, and additional coating materials, additives, or excipients may be further included.
- the sustained-release formulation composition containing the sustained-release microspheres of the present invention is administered to Sprague Dawley Rat (S.D Rat, SD rat)
- the semaglutide is released at 5% or less within 24 hours, and at least 30% or more within 2 weeks or More than 60% can be released within 4 weeks.
- semaglutide was released at 5% or less within 24 hours, 30% or more within 2 weeks, and 60% or more within 4 weeks. It was confirmed (see FIG. 6 and Table 7). In addition, it was confirmed that semaglutide was released in less than 5% within 24 hours in Beagle Dog, more than 30% within 2 weeks, and more than 60% within 4 weeks (FIG. 8, Table 8).
- the sustained-release microspheres of the present invention may be coated with lysine, and the lysine coated on the sustained-release microspheres is 0.01 to 5, 0.01 to 3, 0.01 to 1, or 0.1 to 1 parts by weight based on 100 parts by weight of the sustained-release microspheres before coating. , 0.2 to 0.8 or 0.4 to 0.6 parts by weight may be included.
- the sustained-release preparation composition containing the sustained-release microspheres of the present invention can last for 3 weeks or 1 month or more with a single administration depending on the subject to be administered, so the sustained-release preparation composition of the present invention can It may be administered at intervals of 1 month to 2 months, 1 month to 1.5 months or 1 month.
- T last 35 days
- the duration of the drug effect of semaglutide was longer in beagles than in rats.
- the duration of the drug effect is longer than when administered to a beagle.
- the drug effect may last from 1 month to 3 months, 1 month to 2 months or 1 month to 1.5 months.
- the sustained-release microspheres of the present invention have an average particle size of 5 to 50 ⁇ m, 5 to 40 ⁇ m, 5 to 30 ⁇ m, 10 to 50 ⁇ m, 10 to 40 ⁇ m, 10 to 30 ⁇ m, 10 to 25 ⁇ m, 15 to 50 ⁇ m, 15 to 40 ⁇ m, and 15 to 30 ⁇ m. or 15 to 25 ⁇ m.
- average particle size (D50) means a particle size corresponding to 50% of the volume% in the particle size distribution curve.
- the span value of the sustained-release microspheres of the present invention is 2 or less, and more specifically, the span value is 0.1 to 2, 0.1 to 1.8, 0.3 to 2, 0.3 to 1.8, 0.5 to 2, and 0.5 to 0.5. 1.8, 0.8 to 2, 0.8 to 1.8, 1 to 2, 1 to 1.8 or 1 to 1.6.
- sustained-release microspheres of the present invention or the sustained-release preparation composition containing the same may further include additives and excipients commonly used in the formulation of drugs in the art to which the present invention belongs.
- the sustained-release microspheres of the present invention may further contain at least one protective colloid selected from the group consisting of polyvinyl alcohol, albumin, polyvinylpyrrolidone, gelatin, and the like.
- the protective colloidal material serves to prevent aggregation between microspheres containing semaglutide and improve dispersibility.
- the protective colloid is preferably 0.02 to 1.0% by weight based on the total weight of the sustained-release microspheres.
- the sustained-release preparation composition containing the sustained-release microspheres according to the present invention can be used to treat diabetes, obesity, non-alcoholic steatohepatitis (NASH) or degenerative brain disease.
- NASH non-alcoholic steatohepatitis
- the degenerative brain disease may be any one selected from the group consisting of Parkinson's disease, Alzheimer's disease, Huntington's disease, Lou Gehrig's disease, Creutzfeldt-Jakob disease, stroke, and multiple sclerosis.
- the sustained-release microspheres of the present invention dissolve the semaglutide or a pharmaceutically acceptable salt thereof and the poly(lactide-co-glycolide) in glacial acetic acid, spray using an ultrasonic spray nozzle, and then use dry air. It can be prepared by volatilizing the solvent.
- the present invention provides a method for preparing sustained-release microspheres with no initial burst, long-term sustained release of a drug, no lag phase, and excellent bioavailability.
- the method for preparing the sustained-release formulation composition of the present invention includes preparing a mixed solution by dissolving semaglutide or a pharmaceutically acceptable salt thereof and poly(lactide-co-glycolide) in an organic solvent; and drying the mixed solution to obtain microspheres.
- the type of poly(lactide-co-glycolide) dissolved together with semaglutide or a pharmaceutically acceptable salt thereof is different for the sustained-release microspheres of the present invention. Same as above.
- the weight ratio of semaglutide and poly(lactide-co-glycolide dissolved in an organic solvent is less than 9% by weight of semaglutide in the prepared sustained-release microspheres.
- the weight ratio of semaglutide and poly(lactide-co-glycolide dissolved in an organic solvent is less than 9% by weight of semaglutide in the prepared sustained-release microspheres.
- the organic solvent is one selected from the group consisting of chloroform, ethyl acetate, methylene chloride, methyl ethyl ketone, alcohol having 1 to 5 carbon atoms, glacial acetic acid, formic acid, dimethylsulfoxide, and n-methylpyrrolidone, or any of these It may be a mixed solvent, preferably glacial acetic acid.
- a spray drying method may be used as a method of obtaining microspheres by drying the mixed solution.
- a mixed solution in which the semaglutide or a pharmaceutically acceptable salt thereof and poly(lactide-co-glycolide) are dissolved is added to a spray dryer at 5 to 20 mL/min, 5 to 15 mL/min, or It may be performed by supplying at a flow rate of 5 to 10 mL/min and supplying dry air at 100 to 200 °C, 100 to 150 °C or 120 to 150 °C.
- the frequency of the spray dryer may be 40 to 80 kHz, 50 to 70 kHz or 55 to 75 kHz, preferably 60 kHz.
- the preparation method of the pharmaceutical composition of the present invention may further include the step of lysine coating by suspending the dried microspheres in an aqueous solution in which lysine hydrochloride is dissolved, after the step of drying the mixed solution to obtain microspheres.
- the concentration of lysine hydrochloride in the aqueous solution in which the lysine hydrochloride is dissolved may be 0.01 M to 1 M, preferably 0.1 M to 0.6 M.
- concentration of lysine hydrochloride is lower than 0.01 M, the surface of the microspheres cannot be sufficiently coated with lysine, and when the concentration is higher than 1 M, the lysine hydrochloride is supersaturated, which is inefficient.
- aqueous solution in which the lysine hydrochloride is dissolved may further contain 1% (W/V) polyvinyl alcohol.
- the present invention provides a method for treating diabetes, obesity, non-alcoholic steatohepatitis or degenerative brain disease, comprising the step of administering the sustained-release formulation composition containing the sustained-release microspheres according to the present invention to a subject.
- the degenerative brain disease may be any one selected from the group consisting of Parkinson's disease, Alzheimer's disease, Huntington's disease, Lou Gehrig's disease, Creutzfeldt-Jakob disease, stroke, and multiple sclerosis.
- the sustained-release preparation composition containing the sustained-release microspheres of the present invention may be administered via an oral or parenteral route, preferably via a parenteral route such as intravenous administration, subcutaneous administration, intramuscular administration, or intraperitoneal administration. .
- the effective dosage of the sustained-release formulation composition according to the present invention can be appropriately adjusted according to the age of the patient, the type and severity of the disease, and the condition of the patient. For example, it may be 0.1 to 10 mg/week based on effective sales. The dose may be administered at one time or administered in divided doses.
- Semaglutide, a GLP-1 agonist, and poly(lactic-co-glycolic acid) (PLGA) or poly(lactic acid) PLA, a biodegradable polymer are completely dissolved in glacial acetic acid to obtain a mixed solution, and then spray dried (Spray drying) process to prepare microspheres.
- the types of biodegradable polymers used for preparing the microspheres are shown in Table 1 below, and the compositions for preparing various microspheres containing semaglutide are shown in Table 2.
- PLGA75A, PLGA75B, PLGA65B, PLGA50A, and PLGA50B were used with Evonik's commercially available resomers, RG752H, RG753H, RG653H, RG502H, and RG503H, respectively.
- the prepared mixed solution is supplied at a flow rate of 7.5mL/min to a spray dryer (EIN System) equipped with an ultrasonic nozzle (Sonictopia, 60kHz) using a liquid peristaltic pump (Master flex, Peristaltic pump), and an oscillator ( Sonictopia, 60kHz) was performed by supplying dry air at 135°C while adjusting the power between 50 and 75%.
- the microspheres prepared through the spray drying process were dispersed in an aqueous solution containing 1% (W/V) polyvinyl alcohol (Mitsubishi Chemical Corporation) and 0.5M L-lysine hydrochloride (Merck) as a protective colloid and stirred for 3 hours.
- microspheres were collected through filtration and washing with distilled water, suspended by adding 10% D-mannitol (ROQUETTE) and 0.5% L-lysine hydrochloride (Merck) solution, and then freeze-dried to obtain sustained-release microspheres of the present invention.
- Table 2 shows the types and blending ratios of biodegradable polymers for each sustained-release microsphere formulation.
- Table 3 shows the amounts of biodegradable polymers (PLGA and PLA), drugs (semaglutide), and solvents used in the preparation of sustained-release microspheres using the spray drying method.
- Example 1 2880.0 135.97 28.8
- Example 2 2880.0 135.97 28.8
- Example 3 3360.0 160.83 33.6
- Example 4 3314.5 213.1 33.2
- Example 5 3264.4 270.63 32.6
- Example 6 3220.0 321.66 32.2 Comparative Example 1 5423.0 87.25 54.2 Comparative Example 2 2643.0 404.51 26.4 Comparative Example 3 2526.0 537.08 25.3 Comparative Example 4 2409.0 669.65 24.1 Comparative Example 5 2880.0 135.97 28.8 Comparative Example 6 2880.0 135.97 28.8 Comparative Example 7 2880.0 135.97 28.8 Comparative Example 8 2880.0 135.97 28.8 Comparative Example 9 2880.0 135.97 28.8 Comparative Example 10 2880.0 135.97 28.8 Comparative Example 11 2880.0 135.97 28.8 Comparative Example 12 2880.0 135.97 28.8
- the “average” particle size and distribution of the prepared microspheres were quantitatively measured. Put 180 mg of microspheres and 10mL of 1% PVA into a 50mL conical tube, put them in an ultrasonic generator for 1 minute, disperse them, and put them in a particle size analyzer (CILAS, French) to measure the particle size. was measured. As an index of particle size size uniformity, the span value was obtained by Equation 1 below.
- Table 4 shows the average particle size and span value of the prepared microspheres.
- the initial release gradually increased, and when the drug content exceeded 9%, the initial release increased rapidly (see FIG. 2). Accordingly, it was determined that the maximum loading amount of the drug in the microspheres without rapid initial release was less than 9% (w/w).
- Table 5 shows the initial release change (in vitro release test, after 6 hours and 24 hours) according to the loading amount of the drug (semaglutide).
- An oral glucose tolerance test was performed to confirm the hypoglycemic effect of the sustained-release microspheres containing the semaglutide of the present invention.
- the experiment was conducted by dividing 18 8-week-old S.D. rats (6 rats in each group) into 3 groups. It was divided into a negative control group (Control), a positive control group (API), and the Example 3 formulation administration group (PT403)), and the positive control group (API) was subcutaneously injected once with 0.123 mpk of semaglutide, and the Example 3 formulation administration group ( PT403) injected the Example 3 formulation subcutaneously at 4 mpk.
- Control negative control group
- API positive control group
- PT403 Example 3 formulation administration group
- Example 3 As shown in FIG. 3 , the group administered with the formulation of Example 3 (PT403) induced a decrease in glucose level in a time-dependent manner, and in particular, the hypoglycemic effect was maintained until about the 21st day.
- the positive control group (API) had a hypoglycemic effect on day 1, but returned to normal on day 7 (FIG. 3).
- the body weight of each rat was measured over time, and the Example 3 formulation administration group (PT403) showed a statistically significant weight loss of about 10% compared to the positive control group (API) as well as the negative control group. effect was shown (FIG. 4).
- the sustained-release preparation composition containing semaglutide of the present invention is a formulation capable of maintaining an effect for a long time with only a single administration.
- Microspheres containing semaglutide were administered to 8-week-old S.D. rats, and blood was collected at regular time intervals to evaluate the concentration of the drug in blood and to evaluate the release pattern of the drug in the microspheres in the body.
- Formulations used in the PK test were the formulations of Examples 3, 4 and 6. The amount of drug (semaglutide) administered to rats was the same at 4 mpk regardless of the formulation.
- Formulations of Examples 3, 4 and 6 were administered to 8-week-old male S.D. After subcutaneous injection (S.C) to rats, semaglutide blood concentration was observed over time. 1 hour, 3 hours, 6 hours, 24 hours, 3 days, 5 days, 7 days, 9 days, 11 days, 14 days, 16 days, 18 days, 21 days, 24 days, 28 days, 31 days and On the 35th day, 0.5 ml of blood was collected from the jugular vein and stored at -80°C. After that, LC-MS/MS analysis was performed.
- S.C subcutaneous injection
- the relative bioavailability was compared by obtaining the AUC (area under the curve) from the blood concentration curve over time (FIG. 5). As a result, it was confirmed that the bioavailability increased as the contained drug content increased. In particular, It was confirmed that the microspheres of Example 6, in which the content of semaglutide was 6% by weight, showed the best bioavailability.
- Table 7 shows the PK parameters in SD rats of Examples 3, 4, and 6, and Table 8 shows the cumulative release rate of semaglutide.
- Example 3 was used as the formulation used in the PK test of beagle dogs following rats, and the amount of drug administered was 4mpk, the same as in Experimental Example 3.
- Example 3 After subcutaneous injection (S.C) of the formulation to male beagles, semaglutide blood concentration was observed over time. 1 hour, 3 hours, 6 hours, 24 hours, 3 days, 5 days, 7 days, 9 days, 11 days, 14 days, 16 days, 18 days, 21 days, 23 days, 25 days, 28 days after injection; On days 31, 35, 38, 42, 45, 49, 56, 63, and 70, 1 ml of blood was collected from the jugular vein and stored at -80°C, followed by LC-MS/MS analysis. performed.
- S.C subcutaneous injection
- the relative bioavailability was compared by obtaining the area under the curve from the blood concentration curve over time (FIG. 7), and it was confirmed that the release duration of semaglutide was longer in the beagle compared to the SD rat.
- Table 9 shows the PK parameters for the Example 3 formulation in beagles, and Table 10 shows the cumulative release rate of semaglutide.
- Example 3 the formulations of Comparative Examples 13 and 14 containing liraglutide were subcutaneously injected (S.C) to rats Liraglutide blood concentration over time observed.
- Table 11 shows Comparative Examples 13 and 14 formulation components.
- liraglutide is a peptide of the same GLP-1 RA family with a structure similar to semaglutide of the present invention, almost no drug release itself was observed. Through this, it can be seen that it is difficult to predict what kind of effect will be shown when the type of peptide contained is different even if the biodegradable polymer is used under the same conditions.
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
구분 | Polymer grade | Viscosity (dL/g) |
1 | Poly(D,L-lactide) (PLA) | 0.16 - 0.24 |
2 | Poly(D,L-lactide-co-glycolide) (75:25) (PLGA75A) | 0.14 - 0.22 |
3 | Poly(D,L-lactide-co-glycolide) (75:25)(PLGA75B) | 0.32 - 0.44 |
4 | Poly(D,L-lactide-co-glycolide) (65:35) (PLGA65) | 0.32 - 0.44 |
5 | Poly(D,L-lactide-co-glycolide) (50:50) (PLGA50A) | 0.16 - 0.24 |
6 | Poly(D,L-lactide-co-glycolide)(50:50) (PLGA50B) | 0.32 - 0.44 |
PLGA75A: RG752H / PLGA75B: RG753H / PLGA65B: RG653H / PLGA50A: RG502H / PLGA50B: RG503H / |
구분 | 생분해성 고분자 종류 및 배합비 | 약물 loading (%(w/w)) | ||
고분자종류(1) | 고분자종류(2) | (1):(2) 배합비 |
||
실시예 1 | PLGA50A | PLGA50B | 1:1 | 3 |
실시예 2 | PLGA50A | PLGA50B | 1:3 | 3 |
실시예 3 | PLGA50A | PLGA50B | 1:2 | 3 |
실시예 4 | PLGA50A | PLGA50B | 1:2 | 4 |
실시예 5 | PLGA50A | PLGA50B | 1:2 | 5 |
실시예 6 | PLGA50A | PLGA50B | 1:2 | 6 |
비교예 1 | PLGA50A | PLGA50B | 1:2 | 1 |
비교예 2 | PLGA50A | PLGA50B | 1:2 | 9 |
비교예 3 | PLGA50A | PLGA50B | 1:2 | 12 |
비교예 4 | PLGA50A | PLGA50B | 1:2 | 15 |
비교예 5 | PLA | - | 1:0 | 3 |
비교예 6 | PLGA75A | - | 1:0 | 3 |
비교예 7 | PLGA75B | - | 1:0 | 3 |
비교예 8 | PLGA65B | - | 1:0 | 3 |
비교예 9 | PLGA50A | - | 1:0 | 3 |
비교예 10 | PLGA50B | - | 1:0 | 3 |
비교예 11 | PLGA50A | PLGA75A | 1:1 | 3 |
비교예 12 | PLGA50A | PLA | 1:1 | 3 |
구분 | 고분자사용량(mg) | 약물 사용량(mg) | 용매 사용량(mL) |
실시예 1 | 2880.0 | 135.97 | 28.8 |
실시예 2 | 2880.0 | 135.97 | 28.8 |
실시예 3 | 3360.0 | 160.83 | 33.6 |
실시예 4 | 3314.5 | 213.1 | 33.2 |
실시예 5 | 3264.4 | 270.63 | 32.6 |
실시예 6 | 3220.0 | 321.66 | 32.2 |
비교예 1 | 5423.0 | 87.25 | 54.2 |
비교예 2 | 2643.0 | 404.51 | 26.4 |
비교예 3 | 2526.0 | 537.08 | 25.3 |
비교예 4 | 2409.0 | 669.65 | 24.1 |
비교예 5 | 2880.0 | 135.97 | 28.8 |
비교예 6 | 2880.0 | 135.97 | 28.8 |
비교예 7 | 2880.0 | 135.97 | 28.8 |
비교예 8 | 2880.0 | 135.97 | 28.8 |
비교예 9 | 2880.0 | 135.97 | 28.8 |
비교예 10 | 2880.0 | 135.97 | 28.8 |
비교예 11 | 2880.0 | 135.97 | 28.8 |
비교예 12 | 2880.0 | 135.97 | 28.8 |
구분 |
미립구
평균 입도 (μm) |
스팬값(Span Value) |
실시예 1 | 19.50 | 1.48 |
실시예 2 | 20.80 | 1.49 |
실시예 3 | 20.48 | 1.54 |
실시예 4 | 20.77 | 1.49 |
실시예 5 | 21.35 | 1.47 |
실시예 6 | 21.12 | 1.48 |
비교예 1 | 21.52 | 1.52 |
비교예 2 | 21.48 | 1.49 |
비교예 3 | 22.37 | 1.42 |
비교예 4 | 23.53 | 1.55 |
비교예 5 | 19.85 | 1.43 |
비교예 6 | 20.12 | 1.43 |
비교예 7 | 21.61 | 1.52 |
비교예 8 | 21.63 | 1.53 |
비교예 9 | 23.35 | 1.42 |
비교예 10 | 20.17 | 1.53 |
비교예 11 | 19.62 | 1.42 |
비교예 12 | 18.39 | 1.61 |
구분 | 생분해성 고분자 종류 및 배합비 | 약물 loading (%(w/w)) | 초기 방출(%) | |||
저점도 고분자 (점도:0.14-0.24 dL/g |
고점도 고분자 (점도: 0.32-0.44d L/g) |
배합비 | 6시간 | 1일 | ||
실시예 3 | PLGA50A | PLGA50B | 1:2 | 3 | 0.17 | 1.6 |
실시예 6 | PLGA50A | PLGA50B | 1:2 | 6 | 0.44 | 7.5 |
비교예 1 | PLGA50A | PLGA50B | 1:2 | 1 | 0.16 | 1.5 |
비교예 2 | PLGA50A | PLGA50B | 1:2 | 9 | 2.63 | 27.2 |
비교예 3 | PLGA50A | PLGA50B | 1:2 | 12 | 6.61 | 49.4 |
비교예 4 | PLGA50A | PLGA50B | 1:2 | 15 | 10.6 | 90.4 |
구분 | 생분해성 고분자 종류 및 배합비 | 약물 loading (%(w/w)) | 초기 방출(%) | ||
저점도 고분자 (점도:0.14-0.24 dL/g |
고점도 고분자 (점도: 0.32-0.44d L/g) |
배합비 | 1일 | ||
실시예 1 | PLGA50A | PLGA50B | 1:1 | 3 | 2.8 |
실시예 2 | PLGA50A | PLGA50B | 1:3 | 3 | 2.6 |
실시예 3 | PLGA50A | PLGA50B | 1:2 | 3 | 1.6 |
비교예 5 | PLA | - | 1:0 | 3 | 17.5 |
비교예 6 | PLGA75A | - | 1:0 | 3 | 10.6 |
비교예 9 | PLGA50A | - | 1:0 | 3 | 6.5 |
비교예 7 | - | PLGA75B | 0:1 | 3 | 1.3 |
비교예 8 | - | PLGA65B | 0:1 | 3 | 1.2 |
비교예 10 | - | PLGA50B | 0:1 | 3 | 1.4 |
비교예 11 | PLGA50A+ PLGA75A (1:1) | - | 1:0 | 3 | 10.5 |
비교예 12 | PLGA50A+PLA (1:1) | - | 1:0 | 3 | 101.4 |
PK parameter | 실시예 3 | 실시예 4 | 실시예 6 |
Initial burst (ng/ml) |
15.22 ± 6.14 | 16.69 ± 4.32 | 117.00 ± 18.87 |
InitialTime (hour) | 6.00 ± 0.00 | 9.60 ± 8.05 | 13.20 ± 9.86 |
Cmax(ng/ml) | 175.30 ± 47.53 | 321.42 ± 148.15 | 503.76 ± 144.26 |
Tmax(day) | 14.40 ± 0.89 | 5.00 ± 0.00 | 8.60 ± 3.29 |
AUClast(ng*day/ml) | 1645.53 ± 423.62 | 3074.21 ± 988.85 | 5320.62 ± 1206.39 |
AUC3-28d(ng*day/ml) | 1621.11 ± 419.66 | 3038.06 ± 984.46 | 5080.06 ± 1164.19 |
누적 방출률 (%) | 실시예 3 | 실시예 4 | 실시예 6 |
1일 | 0.58 | 0.52 | 2.01 |
7일 | 16.74 | 29.84 | 33.29 |
14일 | 65.89 | 76.04 | 83.25 |
21일 | 97.86 | 99.43 | 99.03 |
28일 | 99.92 | 99.98 | 99.97 |
PK parameter | 실시예 3 |
Initial burst (ng/ml) |
32.91 ± 11.71 |
InitialTime (day) | 1.40 ± 0.89 |
Cmax(ng/ml) | 784.07 ± 327.44 |
Tmax(day) | 13.40 ± 7.77 |
AUClast(ng*day/ml) | 12671.82 ± 4336.49 |
누적 방출률 (%) | 실시예 3 |
1일 | 0.22 |
7일 | 17.13 |
14일 | 38.69 |
21일 | 75.62 |
28일 | 94.61 |
구분 | 유효성분 | 생분해성 고분자 종류 및 배합비 | 약물 loading (%(w/w)) | ||
고분자 종류(1) | 고분자 종류(2) | (1):(2) 배합비 | |||
비교예 13 | 리라글루타이드 | PLGA50A | PLGA50B | 1:2 | 5 |
비교예 14 | 리라글루타이드 | PLGA50A | PLGA50B | 1:1 | 5 |
Claims (16)
- 세마글루타이드 또는 이의 약학적으로 허용가능한 염과 폴리(락타이드-코-글라이콜라이드)를 포함하는 서방형 미립구를 포함하고,상기 세마글루타이드 또는 이의 약학적으로 허용가능한 염은 상기 서방형 미립구의 3 중량% 이상 9 중량% 미만으로 포함되며,상기 폴리(락타이드-코-글라이콜라이드)는 고유점도가 0.14 내지 0.24 dL/g인 저점도 PLGA 및 고유점도가 0.32 내지 0.44dL/g인 고점도 PLGA의 혼합물인 서방형 제제 조성물.
- 청구항 1에 있어서, 상기 혼합물 내의 상기 저점도 PLGA와 상기 고점도 PLGA의 중량비는 1: 0.2 내지 5인, 서방형 제제 조성물.
- 청구항 1에 있어서, 상기 고점도 PLGA의 락타이드 대 글라이콜라이드의 몰 비율이 50: 45 내지 55인, 서방형 제제 조성물.
- 청구항 1에 있어서, 상기 서방형 미립구는 상기 세마글루타이드 또는 이의 약학적으로 허용가능한 염과 상기 폴리(락타이드-코-글라이콜라이드)를 빙초산에 용해시키고 초음파 분무 노즐을 이용하여 분사한 후 건조 공기를 이용하여 용매를 휘발시켜 제조된 것인, 서방형 제제 조성물.
- 청구항 4에 있어서, 상기 초음파 분무 노즐의 주파수는 60kHz인, 서방형 제제 조성물.
- 청구항 1에 있어서, S.D 랫드에 투여된 후 상기 세마글루타이드가 24시간 이내에 5% 미만으로 방출되고, 2주 이내에 30% 이상 또는 4주 이내에 60% 이상 방출되는, 서방형 제제 조성물.
- 청구항 1에 있어서, 대상에 1개월 내지 3개월 간격으로 투여되는, 서방형 제제 조성물.
- 청구항 1에 있어서, 상기 폴리(락타이드-코-글라이콜라이드)는 상기 서방형 미립구의 91 내지 97 중량%인, 서방형 제제 조성물.
- 청구항 1에 있어서, 상기 서방형 미립구는 평균 입도가 15 내지 25μm인, 서방형 제제 조성물.
- 청구항 1에 있어서, 당뇨, 비만, 비알코올성 지방간염 또는 퇴행성 뇌질환 치료용, 서방형 제제 조성물.
- 청구항 10에 있어서, 상기 퇴행성 뇌질환은 파킨슨병, 알츠하이머병, 헌팅턴병, 루게릭병, 크로이츠펠트-야콥병, 뇌졸중 및 다발성 경화증으로 이루어진 군에서 선택되는 어느 하나인, 서방형 제제 조성물.
- 세마글루타이드 또는 이의 약학적으로 허용가능한 염과 폴리(락타이드-코-글라이콜라이드)를 유기 용매에 용해하여 혼합용액을 제조하는 단계; 및상기 혼합용액을 건조하여 미립구를 얻는 단계를 포함하고,상기 폴리(락타이드-코-글라이콜라이드)는 고유점도가 0.14 내지 0.24 dL/g인 저점도 PLGA 및 고유점도가 0.32 내지 0.44dL/g인 고점도 PLGA의 혼합물인, 서방형 제제 조성물의 제조방법.
- 청구항 12에 있어서, 상기 혼합물 내의 상기 저점도 PLGA와 상기 고점도 PLGA의 중량비는 1: 0.2 내지 5인, 서방형 제제 조성물의 제조방법.
- 청구항 12에 있어서, 상기 고점도 PLGA의 락타이드 대 글라이콜라이드의 몰 비율이 50: 45 내지 55인, 서방형 제제 조성물의 제조방법.
- 청구항 12에 있어서, 상기 혼합용액의 건조는 분무 건조법에 의하여 수행되는 것인, 서방형 제제 조성물의 제조방법.
- 청구항 1 내지 10 중 어느 한 항의 서방형 제제 조성물을 대상에 투여하는 단계를 포함하는, 당뇨, 비만, 비알코올성 지방간염 또는 퇴행성 뇌질환의 치료 방법.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112023025201A BR112023025201A2 (pt) | 2021-06-23 | 2022-06-23 | Composição de formulação de liberação sustentada compreendendo semaglutida, método para a produção de uma composição de formulação de liberação sustentada e uso da dita composição para tratar diabetes, obesidade, esteato-hepatite não alcoólica ou doença cerebral degenerativa |
CN202280044194.8A CN117545471A (zh) | 2021-06-23 | 2022-06-23 | 包含塞马格鲁肽或其药学上可接受的盐的缓释制剂组合物 |
CA3222421A CA3222421A1 (en) | 2021-06-23 | 2022-06-23 | Sustained release formulation composition comprising semaglutide or pharmaceutically acceptable salt thereof |
EP22828803.1A EP4360623A1 (en) | 2021-06-23 | 2022-06-23 | Sustained release formulation composition comprising semaglutide or pharmaceutically acceptable salt thereof |
AU2022298186A AU2022298186A1 (en) | 2021-06-23 | 2022-06-23 | Sustained release formulation composition comprising semaglutide or pharmaceutically acceptable salt thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163213805P | 2021-06-23 | 2021-06-23 | |
US63/213,805 | 2021-06-23 | ||
KR10-2022-0077146 | 2022-06-23 | ||
KR1020220077146A KR20220170782A (ko) | 2021-06-23 | 2022-06-23 | 세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 제제 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022270956A1 true WO2022270956A1 (ko) | 2022-12-29 |
Family
ID=84538519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/008984 WO2022270956A1 (ko) | 2021-06-23 | 2022-06-23 | 세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 제제 조성물 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP4360623A1 (ko) |
KR (1) | KR20220170782A (ko) |
CN (1) | CN117545471A (ko) |
AU (1) | AU2022298186A1 (ko) |
BR (1) | BR112023025201A2 (ko) |
CA (1) | CA3222421A1 (ko) |
WO (1) | WO2022270956A1 (ko) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006097537A2 (en) | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Acylated glp-1 compounds |
KR20190064509A (ko) * | 2017-11-30 | 2019-06-10 | 주식회사 지투지바이오 | 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법 |
KR102137786B1 (ko) * | 2018-07-19 | 2020-07-24 | 주식회사 아울바이오 | 주사제용 미립구의 제조방법 |
KR20200135922A (ko) * | 2019-02-18 | 2020-12-04 | (주)아이엠디팜 | 서방성 지질 전구 제제 및 이를 포함하는 지질 용액 형태의 서방성 주사용 약학 조성물 |
KR20210014086A (ko) * | 2019-07-29 | 2021-02-08 | 주식회사 펩트론 | 레보도파 유발 이상 운동증의 치료 또는 진행 억제용 약학 조성물 |
JP2021183718A (ja) * | 2020-04-27 | 2021-12-02 | クエステック イノベーションズ リミテッド ライアビリティ カンパニー | 付加製造用自己焼戻し鋼 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102235011B1 (ko) | 2018-04-30 | 2021-04-01 | 주식회사 지뉴브 | 약물 함유 plga 미립구 및 그의 제조방법 |
WO2019211451A1 (en) | 2018-05-04 | 2019-11-07 | Novo Nordisk A/S | Gip derivatives and uses thereof |
-
2022
- 2022-06-23 CA CA3222421A patent/CA3222421A1/en active Pending
- 2022-06-23 WO PCT/KR2022/008984 patent/WO2022270956A1/ko active Application Filing
- 2022-06-23 AU AU2022298186A patent/AU2022298186A1/en active Pending
- 2022-06-23 CN CN202280044194.8A patent/CN117545471A/zh active Pending
- 2022-06-23 EP EP22828803.1A patent/EP4360623A1/en active Pending
- 2022-06-23 BR BR112023025201A patent/BR112023025201A2/pt unknown
- 2022-06-23 KR KR1020220077146A patent/KR20220170782A/ko unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006097537A2 (en) | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Acylated glp-1 compounds |
KR20190064509A (ko) * | 2017-11-30 | 2019-06-10 | 주식회사 지투지바이오 | 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법 |
KR102137786B1 (ko) * | 2018-07-19 | 2020-07-24 | 주식회사 아울바이오 | 주사제용 미립구의 제조방법 |
KR20200135922A (ko) * | 2019-02-18 | 2020-12-04 | (주)아이엠디팜 | 서방성 지질 전구 제제 및 이를 포함하는 지질 용액 형태의 서방성 주사용 약학 조성물 |
KR20210014086A (ko) * | 2019-07-29 | 2021-02-08 | 주식회사 펩트론 | 레보도파 유발 이상 운동증의 치료 또는 진행 억제용 약학 조성물 |
JP2021183718A (ja) * | 2020-04-27 | 2021-12-02 | クエステック イノベーションズ リミテッド ライアビリティ カンパニー | 付加製造用自己焼戻し鋼 |
Also Published As
Publication number | Publication date |
---|---|
AU2022298186A1 (en) | 2023-12-07 |
BR112023025201A2 (pt) | 2024-02-27 |
CA3222421A1 (en) | 2022-12-29 |
KR20220170782A (ko) | 2022-12-30 |
EP4360623A1 (en) | 2024-05-01 |
CN117545471A (zh) | 2024-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1797871B1 (en) | Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof | |
WO2021010719A1 (ko) | 리바스티그민을 포함하는 장기지속형 제제 및 이의 제조방법 | |
WO2018221884A1 (ko) | 방출제어가 용이한 서방성 약물 미립자의 제조방법 | |
WO2021162532A2 (ko) | Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물 | |
WO2020197190A1 (en) | Method for preparing biocompatible polymer-based apixaban-loaded microspheres | |
KR101686986B1 (ko) | 류프로라이드를 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물 | |
JP2006514923A (ja) | 注射可能な新規なデポ製剤 | |
WO2022010317A1 (ko) | 도네페질 함유 서방출성 plga 미립구의 제조방법 | |
EP3031449A1 (en) | Entecavir microspheres and pharmaceutical composition for parenteral administration containing same | |
WO2022270956A1 (ko) | 세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 제제 조성물 | |
KR20100092581A (ko) | 균일한 서방출성 미립구의 제조방법 | |
KR20130100464A (ko) | 엔테카비어 미립구 및 이를 포함하는 비경구투여용 약제학적 조성물 | |
KR102212722B1 (ko) | 로피니롤을 포함하는 마이크로스피어 및 이를 함유하는 주사제 조성물 | |
WO2021242021A1 (ko) | 글루카곤 유사 펩타이드 1 작용제 함유 제어방출 미립구 및 이의 제조방법 | |
AU2019362730B2 (en) | Injectable long-acting naltrexone microparticle compositions | |
WO2023249465A1 (ko) | 엔테카비르를 포함하는 장기지속성 미립구 제제 및 이의 제조방법 | |
WO2023249464A1 (ko) | 약물과 파모산을 함유하는 서방성 미립구 | |
WO2020135576A1 (en) | Naltrexone injectable sustained release formulation | |
KR102451185B1 (ko) | 도네페질 함유 지속방출형 미립구 | |
WO2021261926A1 (ko) | 치매치료를 위한 장기지속형 주사제 | |
WO2019107989A1 (ko) | 피마살탄을 포함하는 고체 분산체 | |
WO2023172021A1 (ko) | 코아세르베이션법을 이용하여 현탁성이 개선된 미립구의 제조방법 | |
WO2024019596A1 (ko) | 5-알파 환원효소 저해제를 포함하는 서방성 제제 | |
WO2023249461A1 (ko) | 도네페질과 파모산을 함유하는 서방성 미립구 | |
WO2023090922A1 (ko) | 날트렉손을 포함하는 서방성 주사용 조성물 및 이의 제조 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22828803 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022298186 Country of ref document: AU Ref document number: AU2022298186 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3222421 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022298186 Country of ref document: AU Date of ref document: 20220623 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2023/014906 Country of ref document: MX |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023025201 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2301008317 Country of ref document: TH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280044194.8 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2023579126 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022828803 Country of ref document: EP Ref document number: 2024101388 Country of ref document: RU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022828803 Country of ref document: EP Effective date: 20240123 |
|
ENP | Entry into the national phase |
Ref document number: 112023025201 Country of ref document: BR Kind code of ref document: A2 Effective date: 20231130 |